Literature DB >> 21222624

Interaction of prolyl oligopeptidase with α-synuclein.

Anne-Marie Lambeir1.   

Abstract

Prolyl oligopeptidase (PO) interacts with α-syncline in vitro. It is a weak interaction that induces a nucleation prone conformation of α-synuclein. PO accelerates aggregation and fibril formation of α-syncline in a process that can be reversed by specific inhibitors and is also influenced by an impairing mutation in the PO active site. There is evidence that PO and α-synuclein also interact intracellularly, especially in conditions where the expression of α-synuclein is high. Specific PO inhibitors reduce the number of cells with α-synuclein inclusions in a cellular model of Parkinson's disease. If these interactions also exist in the human brain, PO may be a target for the treatment of Parkinson's disease and other synucleinopathies. Whether PO also contributes to the normal physiological functions of α-syncline remains an open question, but there are some intriguing parallels between the proposed functions of both proteins that deserve further investigation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21222624     DOI: 10.2174/187152711794653878

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  11 in total

Review 1.  Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors.

Authors:  S Mohammadi; M Dolatshahi; F Rahmani
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

2.  Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.

Authors:  Mari H Savolainen; Xu Yan; Timo T Myöhänen; Henri J Huttunen
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

3.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

4.  The role of Thyrotropin Releasing Hormone in aging and neurodegenerative diseases.

Authors:  Caitlin M Daimon; Patrick Chirdon; Stuart Maudsley; Bronwen Martin
Journal:  Am J Alzheimers Dis (Columbia)       Date:  2013

5.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

6.  Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.

Authors:  Reinis Svarcbahs; Ulrika H Julku; Susanna Norrbacka; Timo T Myöhänen
Journal:  Sci Rep       Date:  2018-01-24       Impact factor: 4.379

7.  Mechanism of Action of Prolyl Oligopeptidase (PREP) in Degenerative Brain Diseases: Has Peptidase Activity Only a Modulatory Role on the Interactions of PREP with Proteins?

Authors:  Pekka T Männistö; J Arturo García-Horsman
Journal:  Front Aging Neurosci       Date:  2017-02-14       Impact factor: 5.750

8.  Prolyl Endopeptidase-Like Facilitates the α-Synuclein Aggregation Seeding, and This Effect Is Reverted by Serine Peptidase Inhibitor PMSF.

Authors:  Gabriel S Santos; William Y Oyadomari; Elizangela A Carvalho; Ricardo S Torquato; Vitor Oliveira
Journal:  Biomolecules       Date:  2020-06-25

9.  Prolyl Oligopeptidase Regulates Dopamine Transporter Oligomerization and Phosphorylation in a PKC- and ERK-Independent Manner.

Authors:  Ulrika H Julku; Maria Jäntti; Reinis Svarcbahs; Timo T Myöhänen
Journal:  Int J Mol Sci       Date:  2021-02-10       Impact factor: 5.923

Review 10.  The Dipeptidyl Peptidase Family, Prolyl Oligopeptidase, and Prolyl Carboxypeptidase in the Immune System and Inflammatory Disease, Including Atherosclerosis.

Authors:  Yannick Waumans; Lesley Baerts; Kaat Kehoe; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Front Immunol       Date:  2015-08-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.